Identification of immune signatures associated with both SARS-CoV-2 infection and lung transplantation.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40749682.
- Also identified by DOI 10.1016/j.xcrm.2025.102262 and PMC identifier 12432355.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lung transplantation (lung-tx) offers the last life-saving option for patients with COVID-19-associated lung injury (CALI). We show that the RBD-specific antibodies are dramatically reduced in these CALI lung-tx patients despite a comparable frequency of CD19<sup>+</sup> B cells in circulating blood between CALI lung-tx patients and sero-negative controls. In contrast, non-transplant COVID-19 groups maintain a high level of RBD-specific antibodies. Single-cell RNA sequencing of white blood cells (WBCs) reveals three populations expanded in CALI lung-tx patients, including "lung-tx CD14<sup>+</sup>FCGR3B(CD16b)<sup>+</sup> neutrophils," "lung-tx CD8<sup>+</sup> T cells," and "KLF2<sup>+</sup> CD4<sup>+</sup> T cells," alongside reduced conventional T and B lymphocytes. Elevated expression of interferon (IFN)-responsive genes as part of COVID-19 molecular signatures is sustained in some clusters of monocytes, Tregs, and B cells in all COVID-19 groups. Multiplex analysis of cytokines and chemokines detects a statistically significant increase in interleukin (IL)-6, IL-8, MCP-1, and MIP-1α in circulating blood, specifically in CALI lung-tx patients.
Medical subject headings
- COVID-19
- Lung Transplantation
- SARS-CoV-2